Research Papers:
Decreased expression of IDH1R132H correlates with poor survival in gastrointestinal cancer
PDF | Full Text | How to cite
Metrics: PDF 2244 views | Full Text 4845 views
Jieying Li1, Jianfei Huang1, Fang Huang1, Qing Jin1, Huijun Zhu1, Xudong Wang2, Meng Chen3
1Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
2Department of Laboratory Medicine & Department of Clinical Tissue Bank, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
3Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH, USA
Correspondence to:
Xudong Wang, email: [email protected]
Keywords: gastrointestinal cancer, IDH1-R132H, prognosis, tissue microarray, immunohistochemistry
Received: April 25, 2016 Accepted: August 25, 2016 Published: September 15, 2016
ABSTRACT
Isocitrate dehydrogenase (IDH1) is an NADP-dependent enzyme that catalyzes the decarboxylation of isocitrate to alpha-ketoglutarate. The IDH1-R132H mutation predicts a better clinical outcome for glioma patients, and the expression of IDH1-R132H correlates with a favorable outcome in patients with brain tumors. Here, we investigated IDH1-R132H expression in both gastric (n=526) and colorectal (n=399) tissues by performing immunohistochemistry analyses on tissue microarrays. We also tested whether IDH1-R132H expression correlated with various clinical parameters. In both gastric and colorectal cancer, expression of IDH1-R132H was associated with tumor stage. Patients with low IDH1-R132H expression had a poor overall survival. Our data indicate that IDH1-R132H expression could be used as a predictive marker of prognosis for patients with gastrointestinal cancer.